CALTX Calliditas Therapeutics AB

Calliditas Therapeutics to Attend 2024 Women in Nephrology (WIN) Leadership Conference

Calliditas Therapeutics to Attend 2024 Women in Nephrology (WIN) Leadership Conference

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT) (“Calliditas”) Chief Executive Officer, Renée Aguiar-Lucander, will participate in a panel during this year’s Women in Nephrology (WIN) Leadership Conference in Los Angeles, CA on August 9 – 10.

The panel, titled “How to be Efficient as a Leader in Academia and Industry,” will focus on the importance of female representation and leadership. On that topic, Aguiar-Lucander notes, “I believe women in the industry have made great strides in terms of leadership positions but there is clearly still significant work to do. The industry remains male-dominated and closed networks still exist. It’s therefore important to shine a light on all of the success that female leaders have achieved and how diversity and a variety of leadership styles continue to successfully drive innovation, growth and profitability. We should publicize and celebrate this positive change whilst improving mentorship and support all of the amazing women in our organizations. If we can do that, I’m hopeful that more women will rise to the top and excel at whatever they set their minds to.”

WIN was founded in 1983 by women in the nephrology field who had a goal of developing and providing mentorship and guidance to all nephrologists and scientists, including those that historically have been under-represented. In alignment with this goal, Aguiar-Lucander will be speaking to her experience in management, the art of building a winning organization as CEO, and the specific impact of the women in leadership at Calliditas.

For more information about this conference, visit the Women in Nephrology website .

About Calliditas

Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in rare diseases with significant unmet medical needs. Calliditas’ common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT). Visit Calliditas.com for further information.

For further information, please contact:

Emma Santos



EN
01/08/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Calliditas Therapeutics AB

 PRESS RELEASE

Calliditas Therapeutics to Present Four Abstracts at American Society ...

Calliditas Therapeutics to Present Four Abstracts at American Society of Nephrology (ASN) Kidney Week 2024 STOCKHOLM, Sweden, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX) (“Calliditas”), today announced upcoming presence and data presentations at the American Society of Nephrology Kidney Week 2024 in San Diego, California on October 23 – 27, 2024. Presentations will highlight an open-label extension study of the efficacy and safety of Nefecon (TARPEYO® (budesonide) delayed release capsules)) in patients with primary immunoglobulin A nephropathy (...

 PRESS RELEASE

Calliditas Therapeutics to Attend 2024 Women in Nephrology (WIN) Leade...

Calliditas Therapeutics to Attend 2024 Women in Nephrology (WIN) Leadership Conference NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT) (“Calliditas”) Chief Executive Officer, Renée Aguiar-Lucander, will participate in a panel during this year’s Women in Nephrology (WIN) Leadership Conference in Los Angeles, CA on August 9 – 10. The panel, titled “How to be Efficient as a Leader in Academia and Industry,” will focus on the importance of female representation and leadership. On that topic, Aguiar-Lucander notes, “I believe women in the industry have ma...

Maria Vara ... (+2)
  • Maria Vara
  • Oscar Haffen Lamm

Coverage update

Given team and strategy changes, Oscar Haffen Lamm is now assuming coverage of Medincell, Camurus, Valneva, Aelis Pharma, Abivax, Calliditas, Egetis Therapeutics, Basilea, Geneuro, Achilles, Valerio, Innate Pharma, Morphosys, Inventiva Pharma, Vicore, DBV Technologies, and Genfit.Maria Vara is now

Alex Cogut
  • Alex Cogut

Coverage update

Given team and strategy changes, Alex Cogut is now assuming coverage of Achilles Therapeutics, Adaptimmune Therapeutics, Autolus, Calliditas, Cellectis, Galapagos, GenSight, Hansa Biopharma, Heidelberg Pharma, Immunocore, Innate Pharma, Sesorion and ValerioWe drop coverage of Celyad Oncology BioNte

 PRESS RELEASE

Calliditas Announces Publication of Cost-Effectiveness Analysis of Nef...

Calliditas Announces Publication of Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with IgA Nephropathy in the United States NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced the publication of a cost-effective analysis of Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules) versus standard of care (SOC) for people with Primary IgA Nephropathy (IgAN) in the United States (US). The analysis was published in the peer-reviewed journal . ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch